KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of “Hold” by Analysts

KALA BIO, Inc. (NASDAQ:KALA) has received an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $1,018.75.

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of KALA BIO to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of KALA BIO in a report on Friday, March 27th.

KALA BIO Stock Up 4.7%

Shares of NASDAQ KALA opened at $2.65 on Friday. KALA BIO has a 52 week low of $2.52 and a 52 week high of $1,030.00. The firm’s fifty day moving average is $8.40 and its 200 day moving average is $22.56. The company has a market cap of $49.26 million, a price-to-earnings ratio of -0.03 and a beta of -2.23.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($8.50) by $8.36.

Institutional Trading of KALA BIO

Large investors have recently added to or reduced their stakes in the stock. Woodline Partners LP bought a new stake in KALA BIO in the first quarter valued at $1,483,000. Virtu Financial LLC bought a new stake in KALA BIO in the fourth quarter valued at $48,000. Jane Street Group LLC bought a new stake in KALA BIO in the fourth quarter valued at $80,000. XTX Topco Ltd bought a new stake in KALA BIO in the second quarter valued at $62,000. Finally, Geode Capital Management LLC boosted its holdings in KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after acquiring an additional 1,534 shares in the last quarter. Institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.